Bringing the Oncology Community Together

EGFR Mutation Not a Prognostic Factor for NSCLC

Beth Fand Incollingo
Published Online: Thursday, February 28, 2013
Dr Young Tae Kim

Young Tae Kim, MD

Although the presence of an epidermal growth factor receptor (EGFR) mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor (TKI) therapy in patients with non-small cell lung cancer (NSCLC), the mutation is not a prognostic factor, according to a study in the Journal of Thoracic Oncology.

Previous studies that sought to determine the utility of EGFR as a prognostic factor in NSCLC have had mixed results, possibly due to confounding factors such as clinical characteristics and the small sizes of the study populations. In this study, the authors investigated EGFR as a prognostic marker in patients who underwent complete resection for NSCLC.

In the study conducted at Seoul National University Hospital, investigators retrospectively collected samples from patients with NSCLC, 636 with adenocarcinoma and 227 with squamous cell carcinoma. Of those patients, 354 had an EGFR mutation. The patients had been seen at the hospital between June 1998 and February 2010, and all had undergone surgery for their disease.

EGFR mutations were frequently seen in adenocarcinoma in younger women who had never smoked and had early-stage disease. A univariate analysis of those patients found that bronchioloalveolar carcinoma pattern and the presence of the EGFR mutation were associated with better long-term survival. However, because there were tight correlations between the presence of EGFR mutation and good clinical variables, the authors also performed a multivariate analysis using Cox’s proportional hazard model to correct hidden confounding effects.

In the multivariate analysis, only age (hazard ratio [HR] = 1.037; 95% CI, 1.014-1.061; P = .002), status as a never-smoker (HR = 2.374; 95% CI, 1.496-3.769; P = .000), and pathologic stage (stage II: HR = 2.389; 95% CI, 1.340-4.259; P = .003; stage III: HR = 3.299; 95% CI, 1.964-5.541; P = .000; stage IV: HR = 6.374; 95% CI, 3.040-13.366; P = .000) remained significant prognostic factors.

Pathologic stage was the only independent prognostic factor in a multivariate analysis for recurrence (stage II: HR = 2.019; 95% CI, 1.376-2.962; P = .000; stage III: HR = 2.351; 95% CI, 1.705-3.241; P = .000; stage IV: HR = 6.549; 95% CI, 4.076-10.523; P = .000). After recurrence, only smoking status remained as a prognostic factor for survival (HR = 2.152; 95% CI, 1.223- 3.788; P = .008).

Among patients with the EGFR mutation, treatment with EGFR TKIs was associated with longer survival compared with conventional chemotherapy (P = .001).

Because the EGFR mutation is rarely detected in squamous cell carcinoma, the authors performed the same analysis for only adenocarcinoma. Similar results were observed, except that age was not a significant variable in the multivariate analysis for overall survival.

The study is one of the largest to test the value of the EGFR mutation after surgery as a prognostic marker. The results suggest that the presence of the mutation may not be a true prognostic factor for long-term survival in NSCLC.

“The clinical observation that patients with EGFR mutation seem to survive longer may be because EGFR mutation is more frequently associated with other significant prognostic factors, such as age, stage, or smoking status,” the authors wrote. “On the basis of our results, the pathologic stage seems to affect the prognosis by influencing cancer recurrence, and smoking status seems to be the most important prognostic factor for overall survival.”
Kim YT, Seong YW, Jung YJ, et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of nonsmall cell lung cancer. J Thorac Oncol. 2013;8(2):171-178.


Related Articles
First- and Later-line Use of Panitumumab in mCRC
Panelists describe the results of clinical trials of the EGFR inhibitor panitumumab as first-line or later-line therapy for patients with metastatic colorectal cancer and the importance of RAS testing for patient selection.
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
Treatment of Unresectable RAS Wild-type Metastatic CRC
Panelists discuss the frontline treatment of patients with unresectable metastatic colorectal cancer, which has become a more challenging decision in recent years as a result of studies focused on RAS mutations.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.